Growth Factors:Potential Therapeutic Applications in Neurology
JNNP 54:1445-1450, Drago,J.,et al, 1994
Optic Neuritis, Prognosis for Multiple Sclerosis from MRI, CSF, and HLA Findings
Neurol 50:708-714, Soderstrom,M.,et al, 1998
Herpes Simplex & the Human Nervous System
Milit Med 140:765, Finelli,P.F., 1975
Numb Chin Syndrome
UptoDate.com Sept, Robertson, C.E., 2018
JC Virus Infection of the Brain
AJNR 31:1564-1576, Bag,A.K.,et al, 2010
Early MRI in Optic Neuritis: The Risk for Disability
Neurol 72:542-550, Swanton,.K.,et al, 2009
Pediatric Optic Neuritis: Brain MRI Abnormalities and Risk of Multiple Sclerosis
Neurol 72:881-885, Bonhomme,G.R.,et al, 2009
Mlutiple Sclerosis Risk After Optic Neuritis: Final Optic Neuritis Treatment Trial Follow-Up
Arch Neurol 65:727-732, The Optic Neuritis Study Group, 2008
The Clinical Features, MRI Findings, and Outcome of Optic Neuritis in Children
Neurol 67:258-262, Wilejto,M.,et al, 2006
High- and Low-Risk Profiles for the Development of Multiple Sclerosis Within 10 Years After Optic Neuritis
Arch Ophthalmol 121:944-949, Optic Neuritis Study Group, 2003
Recent Developments in Neurology
BMJ 324:656-660, Wiebe,S.,&Nicolle,M.W., 2002
Management of Acute Optic Neuritis
Lancet 360:1953-1962, Hickman,S.J.,et al, 2002
Optic Neuritis in Multiple Sclerosis: An Update
The Neurologist 6:205-213, Chan,J.W., 2000
Acute Leukoencephalopathies:Differential Diagnosis and Investigation
The Neurologist 4:148-166, Weinshenker,B.G.,et al, 1998
The Predictive Value of CSF Ologoclonal Banding for MS 5 Years After Optic Neuritis
Neurol 51:885-887, Cole,S.R.,et al, 1998
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
HLA Typing in Acute Optic Neuritis, Relation to MS & Magnetic Resonance Imaging Findings
Arch Neurol 54:76-80, Frederiksen,J.L.,et al, 1997
Correlation of Clinical, Magnetic Resonance Imaging, and Cerebrospinal Fluid Findings in Optic Neuritis
Ann Neurol 41:392-398, Jacobs,L.D.,et al, 1997
The 5-Year Risk of MS After Optic Neuritis
Experience of the Optic Neuritis Trtm Trial, Optic Neuritis Study Group, Neurol 49:1404-1413997., , 1997
Risk Factors for Developing Multiple Sclerosis after Childhood Optic Neuritis
Neurol 49:11413-1418, Lucchinetti,C.F.,et al, 1997
Bilateral Simultaneous Optic Neuropathy in Adults:Clinical, Imaging, Serological, and Genetic Studies
JNNP 58:70-74, Morrissey,S.P.,et al, 1995
Optic Neuritis:A Population-Based Study in Olmsted County, Minnesota
Neurol 45:244-250, Rodriquez,M.,et al, 1995
Brain Magnetic Resonance Imaging in Acute Optic Neuritis, Experience of the Optic Neuritis Study Group
Arch Neurol 50:841-846, Beck,R.W.,et al, 1993
Relapsing and Remitting Human Immunodeficiency Virus-Associated Leukoencephalomyelopathy
Ann Neurol 31:34-38, Berger,J.R.,et al, 1992
Clinical and Magnetic Resonance Imaging in Optic Neuritis
Neurol 41:15-19, Jacobs,L.,et al, 1991
Uhthoff's Symptom in Optic Neuritis:Relationship to Magnetic Resonance Imaging & Development of Multiple Sclerosis
Ann Neurol 30:180-184, Scholl,G.B.,et al, 1991
Retroviruses and Multiple Sclerosis. I. Analysis of Seroreactivity by Western Blot and Radioimmune Assay
Neurol 40:1251-1253, Weinshenker,B.G.,et al, 1990
Retroviruses & Multiple Sclerosis. II. Failure of Gene Amplification Techniques to Detect Viral Sequences
Neurol 40:1254-1258, Dekaban,G.A.&Rice,G.P.A., 1990
A Long-Term Prospective Study of Optic Neuritis:Evaluation of Risk Factors
Ann Neurol 27:386-393, Sandberg-Wollheim,M.,et al, 1990
HTLV-I Sequences Are Not Detected in Peripheral Blood Genomic DNA or in Brain cDNA of MS Patients
Ann Neurol 28:574-577, Oksenberg,J.R.,et al, 1990
Failure to Detect Human T-Cell Leukemia Virus-Related Sequences in Multiple Sclerosis Blood
Arch Neurol 47:1064-1065, Chen,I.S.Y.,et al, 1990
No Evidence for Human T-Cell Leukemia Virus Type I or Human T-Cell Leukemia Virus Type II Infection in Patients with MS
Arch Neurol 47:1061-1063, Perl,A.,et al, 1990
Risk Factors for Multiple Sclerosis:Race or Place? Editorial
JNNP 53:821-823, 903, 906990., Compston,A., 1990
Multiple Sclerosis-Like Illness Occurring with Human Immunodeficiency Virus Infection
Neurol 39:324-329, Berger,J.R.,et al, 1989
Risk of Developing Multiple Sclerosis after Uncomplicated Optic Neuritis:A Long-Term Prospective Study
Neurol 38:185-190, Rizzo,J.F.&Lessell,S., 1988
The Geography of Neurology
BMJ 2:506, Spillane,J.D., 1972
The Optic Nerve Should Graduate to Be the Fifth Lesion Site for the Diagnosis of Multiple Sclerosis
Neurol 102:e207919, Galetta,S. & Brownlee, W., 2024
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
NEJM 390:589-600, 662, Vermersch,P.,et al, 2024
Management of Possible Multiple Sclerosis
NEJM 388:2195-2190, , 2023
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Progressive Multifocal Leukoencephalopathy in a Patient with Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
JAMA Neurol 78:736-740, Patel,A.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Comorbidity is Associated with Disease Activity in MS
Neurol 95:e446-e456, Salter, A.,et al, 2020
Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020
Two Cases of Meningitis Associated with Ocrelizumab Therapy
Mult Scler Rel Dis 38:101866, Theriault, M. & Solomon, A.J., 2020
Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis
JAMA 32:175-187, Brown, J.W.L.,et al, 2019
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis
JAMA 32:165-174,153, Burt, R.K.,et al, 2019
Simultaneous CMV and Listeria Infection Following Alemtuzumab Treatment for Multiple Sclerosis
Neurol 92:296-298, Pappolla, A.,et al, 2019